A multiple treatment comparison meta‐analysis of monoamine oxidase type B inhibitors for Parkinson's disease

Binde, Caroline Ditlev; Tvete, Ingunn Fride; Gåsemyr, Jørund; Klemp, Marianne

doi:10.1111/bcp.13651

Cited by 58 publications

(57 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously investigated the comparative effectiveness of MAO-B inhibitors available for treatment of Parkinson's disease [4]. We conducted a multiple treatment comparison (MTC) meta-analysis assessing which drug had the highest probability of being the most effective drug for early and late Parkinson's disease.…”

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

Binde

Tvete

Gåsemyr

et al. 2020

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

Purpose To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson's disease. Methods We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson's disease. We extracted and pooled data from included clinical trials in a joint model allowing both direct and indirect comparison of the seven drugs. We considered dopamine agonists and MAO-B inhibitors given as monotherapy or in combination with levodopa. Selected endpoints were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score, serious adverse events and withdrawals. We estimated the relative effectiveness of each dopamine agonist and MAO-B inhibitor versus comparator drug. Results Altogether, 79 publications were included in the analysis. We found all the investigated drugs to be effective compared with placebo when given as monotherapy except safinamide. When considering combination treatment, the estimated relative

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

Binde

Tvete

Gåsemyr

et al. 2020

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…MAO B inhibitors can prevent the breakdown of brain DA by inhibiting MAO B enzyme activities (Finberg, 2019). These MAO B inhibitors include rasagiline, safinamide, and selegiline (Deshwal et al, 2017;Dezsi and Vecsei, 2017;Binde et al, 2018;Szökőet al, 2018). Side effects including nausea or insomnia may happen (Dezsi and Vecsei, 2017).…”

Section: Mao B Inhibitorsmentioning

confidence: 99%

Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease

Liu

Nie

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by neuronal loss and dysfunction of dopaminergic neurons located in the substantia nigra, which contain a variety of misfolded a-synuclein (a-syn). Medications that increase or substitute for dopamine can be used for the treatment of PD. Recently, numerous studies have shown gut microbiota plays a crucial role in regulating and maintaining multiple aspects of host physiology including host metabolism and neurodevelopment. In this review article, the role of gut microbiota in the etiological mechanism of PD will be reviewed. Furthermore, we discussed current pharmaceutical medicine-based methods to prevent and treat PD, followed by describing specific strains that affect the host brain function through the gut-brain axis. We explained in detail how gut microbiota directly produces neurotransmitters or regulate the host biosynthesis of neurotransmitters. The neurotransmitters secreted by the intestinal lumen bacteria may induce epithelial cells to release molecules that, in turn, can regulate neural signaling in the enteric nervous system and subsequently control brain function and behavior through the brain-gut axis. Finally, we proved that the microbial regulation of the host neuronal system. Endogenous a-syn can be transmitted long distance and bidirectional between ENS and brain through the circulatory system which gives us a new option that the possibility of altering the community of gut microbiota in completely new medication option for treating PD.

show abstract

“…A recent meta-analysis of the available clinical data confirms the effectiveness of MAO-B inhibitors both in monotherapy and in combination with levodopa. According to its results, selegiline seems to be the most effective MAO-B inhibitor in the combination therapy (Binde et al 2018). There are several recent reviews discussing the place of MAO-B inhibitors in the therapy of PD (Riederer and Laux 2011;Fabbrini et al 2012;Dezsi and Vecsei 2014;Marsili et al 2017;Dezsi and Vecsei 2017;Riederer and Muller 2018).…”

Section: -Month Open Label Selegiline Treatment Initiated In the Levmentioning

confidence: 99%

Selegiline: a molecule with innovative potential

et al. 2019

View full text Add to dashboard Cite

Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson's disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on-off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson's disease. However, the serious side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors.

show abstract

A multiple treatment comparison meta‐analysis of monoamine oxidase type B inhibitors for Parkinson's disease

Abstract: All of the included MAO-B inhibitors were effective compared to placebo when given as monotherapy. Combination therapy with MAO-B inhibitors and levodopa showed that all three MAO-B inhibitors were effective compared to placebo, but selegiline was the most effective drug.

Cited by 58 publications

References 46 publications

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease

Selegiline: a molecule with innovative potential

Contact Info

Product

Resources

About